DaVita shares fell 3.0% after earnings, with higher-than-forecast technology investment in U.S. dialysis weighing on full-year financial performance. The transcript also points to limited near-term financial contribution from expanded HD: management expects no material net impact on adjusted operating income in 2026 or 2027.
Shares dropped 19.3% following DaVita’s Q2 report as investors reacted negatively to margin compression and a cautious outlook driven by lower sequential revenue per treatment and expected headwinds from declining ACA enrollment and phosphate binder reimbursement.
DaVita's stock surged 25.8% as the company delivered better-than-expected volume growth, raised full-year guidance, and demonstrated early traction from technology investments supporting operational efficiency and clinical outcomes.
DaVita reported a strong third quarter in 2025, achieving adjusted operating income of $517 million and adjusted earnings per share of $2.51, maintaining its trajectory for the full year.